FDA Approves New Oral Drug for Advanced Colorectal Cancer
The U.S. Food and Drug Administration has approved the oral drug Lonsurf (formerly TAS-102)—which is a combination of trifluridine and tipiracil—for the treatment of patients with metastatic colorectal cancer who are no longer responding to other therapies, including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy; an anti-VEGF biological therapy; and if RAS wild-type, an anti-EGFR therapy…
